What is SpanACCESS?
A flexible, longitudinal engine for real-world evidence
SpanACCESS enables customisable, real-world studies using uMed’s pre-consented, EMR-linked patient cohorts. From validated PROs to home-based clinical measures and multi-timepoint data capture, SpanACCESS delivers the depth and precision needed to inform clinical strategy, regulatory submission, and post-market evidence.
Deep, longitudinal insight
Multi-timepoint studies (baseline, 3, 6, 12+ months)
Customisable Study Design
PROs, non-validated surveys, devices, secondary care data
Rich, Multi-Source Data
EHR, ePRO, genetics, devices, home testing, digital endpoints
Rapid recruitment
Activate pre-consented cohorts instantly across UK & US
How it works
Access patients, unlock evidence, generate insights
Using AI-driven patient matching and automated engagement tools, ACCESS Cohorts identify eligible participants, enroll them remotely, and continuously collect clinically linked data — creating a powerful, living evidence ecosystem.
Identify
EHR-based recruitment & screening: Identify eligible trial patients faster and with better accuracy.
Engage
Remote enrolment to ACCESS Cohort. Data-backed messaging optimization: Highlight what matters most to real patients.
Collect & deliver
Live and ongoing collection of EHR, PROs, wearables and hometesting kits unified into a tailored dataset.
Dive deep
Demonstrate real-world value to payers: Show sustained outcomes like weight loss, A1c control, and reduced complications.
Data depth you can shape.
Flexible data modules, built around your study
Pull from any combination of the following:
EHR Data
Comorbidities, diagnosis, biomarkers, hospitalisations
Validated ePROs
Deploy generic Quality of Life and disease specific ePROs.
Non-validated, custom surveys
Design and deploy custom questionnaires to answer specific research questions.
Digital Endpoints & Devices
CGM, ECG patches, DEXA, activity, metabolic rate, sleep tracking
Home-Based Testing
CRP, IL-6, genotype collection, at-home labs
US & UK
Ethics approved protocols
95%
Data completeness
5,500+
Active study participants
US & UK
Dedicated nurse support team
Proven Impact
Real studies. Real results.
BIAL COMTEX
Collected 6,500 patient responses in 5 days, linking PROs to EHRs to reveal prescribing, persistence and unexpected secondary outcomes for GLP-1 therapy.
6,500
Patient responses in 5 days
5-10 days
To survey design & signoff
3-5 days
To live cohort
15 days
To initial insight
“uMed is the only company we’ve found that can offer both real-time access to a live, consented patient pool and their complete EMR data. Their platform is state-of-the-art.”
Glynn Jones, Global HEOR & RWE Lead, BIAL
Start building with ACCESS
Book a complimentary demonstration
Need help with something else?
Get in Touch
